比伐芦定与肝素联合可选糖蛋白IIb/IIIa抑制剂对ST段抬高型心肌梗死患者1年死亡率的影响:EUROMAX随机临床试验二次分析
EUROMAX随机开放标签试验纳入2198例因ST段抬高型心肌梗死(STEMI)转运行直接经皮冠状动脉介入治疗的患者,随机接受比伐芦定单药或普通肝素/低分子肝素联合可选糖蛋白IIb/IIIa抑制剂(GPI)。1年全因死亡率两组均为59例(RR 1.02,95%CI 0.72-1.45,P=.92),心脏死亡和非心脏死亡均无显著差异。
要点
- 比伐芦定组与肝素联合可选GPI组1年全因死亡均为59例,RR 1.02,95%CI 0.72-1.45,P=.92。
- 1年心脏死亡比伐芦定组44例(4.0%)vs 对照组48例(4.3%),RR 0.93,95%CI 0.63-1.39,P=.74。
- 30天至1年死亡比伐芦定组27例(2.5%)vs 对照组25例(2.3%),RR 1.10,95%CI 0.64-1.88,P=.73。
核心结论
- 在因STEMI转运行直接PCI的患者中,比伐芦定与肝素联合可选GPI治疗1年死亡率相似。
- EUROMAX试验中比伐芦定组30天死亡和/或大出血复合终点降低未转化为1年心血管或全因死亡降低。
研究设计与样本
- 国际、随机、开放标签临床试验(EUROMAX),纳入2198例STEMI患者,2010年3月10日至2013年6月20日期间转运行直接PCI,随访1年。
- 患者于救护车按1:1随机接受比伐芦定单药 vs 普通肝素或低分子肝素联合可选GPI(对照组),分析基于意向治疗。
主要发现
- 2198例患者中男1675例(76.2%)、女523例(23.8%),中位年龄62岁(四分位距52-72岁),2164例(98.5%)有完整1年随访数据。
- 1年全因死亡118例(5.4%),两组死亡数相同均为59例(RR 1.02,95%CI 0.72-1.45,P=.92)。
- 1年心脏死亡比伐芦定组44例(4.0%)vs 对照组48例(4.3%),RR 0.93,95%CI 0.63-1.39,P=.74。
- 1年非心脏死亡比伐芦定组15例(1.4%)vs 对照组11例(1.0%),RR 1.39,95%CI 0.64-3.01,P=.40。
- 30天至1年死亡比伐芦定组27例(2.5%)vs 对照组25例(2.3%),RR 1.10,95%CI 0.64-1.88,P=.73;预设亚组结果一致。
关键数值与推荐
- 主要结局为1年死亡率,所有死亡由独立盲法临床事件委员会裁定为心脏性或非心脏性。
- 1年全因死亡两组均为59例,RR 1.02(95%CI 0.72-1.45,P=.92)。
- 1年心脏死亡比伐芦定组44例(4.0%)vs 对照组48例(4.3%),RR 0.93(95%CI 0.63-1.39,P=.74)。
- 1年非心脏死亡比伐芦定组15例(1.4%)vs 对照组11例(1.0%),RR 1.39(95%CI 0.64-3.01,P=.40)。
- 30天至1年死亡比伐芦定组27例(2.5%)vs 对照组25例(2.3%),RR 1.10(95%CI 0.64-1.88,P=.73)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available regarding long-term mortality in the context of contemporary practice with frequent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors. OBJECTIVE: To assess the effect of bivalirudin monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-year mortality. DESIGN, SETTING, AND PARTICIPANTS: This international, randomized, open-label clinical trial (EUROMAX [European Ambulance Acute Coronary Syndrome Angiography]) included 2198 patients with STEMI undergoing transport for primary percutaneous coronary intervention from March 10, 2010, through June 20, 2013, and followed up for 1 year. Patients were randomized (1:1) in ambulance to bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control group). Analysis was based on intention to treat. MAIN OUTCOMES AND MEASURES: The primary outcome of this prespecified analysis was 1-year mortality. All deaths were adjudicated as cardiac or noncardiac by an independent, blinded clinical events committee. One-year mortality was assessed and examined across multiple prespecified subgroups. RESULTS: Of the 2198 patients enrolled (1675 men [76.2%] and 523 women [23.8%]; median [interquartile range] age, 62 [52-72] years), complete 1-year follow-up data were available for 2164 (98.5%). All-cause 1-year mortality occurred in 118 patients (5.4%). The number of all-cause deaths was the same for both treatment groups (59 deaths; relative risk [RR], 1.02; 95% CI, 0.72-1.45; P = .92). No differences were noted in the rates of 1-year cardiac death (44 [4.0%] for the bivalirudin group vs 48 [4.3%] for the control group; RR, 0.93; 95% CI, 0.63-1.39; P = .74) or noncardiac death (15 [1.4%] for the bivalirudin group vs 11 [1.0%] for the control group; RR, 1.39; 95% CI, 0.64-3.01; P = .40). Results were consistent across the prespecified patient subgroups. The rate of deaths occurring from 30 days to 1 year was also similar (27 [2.5%] in the bivalirudin group vs 25 [2.3%] in the control group; RR, 1.10; 95% CI, 0.64-1.88; P = .73). CONCLUSIONS AND RELEVANCE: In patients with STEMI who were being transported for primary percutaneous coronary intervention, treatment with bivalirudin or with heparin with optional use of GPI resulted in similar 1-year mortality. The reduced composite end point of death and/or major bleeding at 30 days in the bivalirudin arm of the EUROMAX trial did not translate into reduced cardiovascular or all-cause death at 1 year. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01087723.
引用
- Fabris E, Kilic S, Van't Hof AWJ, et al. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28273285. doi:10.1001/jamacardio.2016.5975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。